Research ExplorerPublicationsHyperfractionated versus conventional radiotherapy followed ...

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

Standard

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. / Lannering, Birgitta; Rutkowski, Stefan; Doz, Francois; Pizer, Barry; Gustafsson, Göran; Navajas, Aurora; Massimino, Maura; Reddingius, Roel; Benesch, Martin; Carrie, Christian; Taylor, Roger; Gandola, Lorenza; Björk-Eriksson, Thomas; Giralt, Jordi; Oldenburger, Foppe; Pietsch, Torsten; Figarella-Branger, Dominique; Robson, Keith; Forni, Marco; Clifford, Steven C; Warmuth-Metz, Monica; von Hoff, Katja; Faldum, Andreas; Mosseri, Véronique; Kortmann, Rolf.

In: J CLIN ONCOL, Vol. 30, No. 26, 26, 2012, p. 3187-3193.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lannering, B, Rutkowski, S, Doz, F, Pizer, B, Gustafsson, G, Navajas, A, Massimino, M, Reddingius, R, Benesch, M, Carrie, C, Taylor, R, Gandola, L, Björk-Eriksson, T, Giralt, J, Oldenburger, F, Pietsch, T, Figarella-Branger, D, Robson, K, Forni, M, Clifford, SC, Warmuth-Metz, M, von Hoff, K, Faldum, A, Mosseri, V & Kortmann, R 2012, 'Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.', J CLIN ONCOL, vol. 30, no. 26, 26, pp. 3187-3193. <http://www.ncbi.nlm.nih.gov/pubmed/22851561?dopt=Citation>

APA

Lannering, B., Rutkowski, S., Doz, F., Pizer, B., Gustafsson, G., Navajas, A., Massimino, M., Reddingius, R., Benesch, M., Carrie, C., Taylor, R., Gandola, L., Björk-Eriksson, T., Giralt, J., Oldenburger, F., Pietsch, T., Figarella-Branger, D., Robson, K., Forni, M., ... Kortmann, R. (2012). Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J CLIN ONCOL, 30(26), 3187-3193. [26]. http://www.ncbi.nlm.nih.gov/pubmed/22851561?dopt=Citation

Vancouver

Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J CLIN ONCOL. 2012;30(26):3187-3193. 26.

Bibtex

@article{67a2cad7dccc44feaba7f254e08903ba,
title = "Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.",
abstract = "To compare event-free survival (EFS), overall survival (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed by maintenance chemotherapy.",
keywords = "Humans, Male, Female, Adolescent, Child, Survival Rate, Combined Modality Therapy, Disease-Free Survival, Child, Preschool, Recurrence, Chemotherapy, Adjuvant, Cranial Irradiation, Radiotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cerebellar Neoplasms/*radiotherapy, *Dose Fractionation, Hearing Loss/etiology, Medulloblastoma/*radiotherapy, Humans, Male, Female, Adolescent, Child, Survival Rate, Combined Modality Therapy, Disease-Free Survival, Child, Preschool, Recurrence, Chemotherapy, Adjuvant, Cranial Irradiation, Radiotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cerebellar Neoplasms/*radiotherapy, *Dose Fractionation, Hearing Loss/etiology, Medulloblastoma/*radiotherapy",
author = "Birgitta Lannering and Stefan Rutkowski and Francois Doz and Barry Pizer and G{\"o}ran Gustafsson and Aurora Navajas and Maura Massimino and Roel Reddingius and Martin Benesch and Christian Carrie and Roger Taylor and Lorenza Gandola and Thomas Bj{\"o}rk-Eriksson and Jordi Giralt and Foppe Oldenburger and Torsten Pietsch and Dominique Figarella-Branger and Keith Robson and Marco Forni and Clifford, {Steven C} and Monica Warmuth-Metz and {von Hoff}, Katja and Andreas Faldum and V{\'e}ronique Mosseri and Rolf Kortmann",
year = "2012",
language = "English",
volume = "30",
pages = "3187--3193",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

RIS

TY - JOUR

T1 - Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

AU - Lannering, Birgitta

AU - Rutkowski, Stefan

AU - Doz, Francois

AU - Pizer, Barry

AU - Gustafsson, Göran

AU - Navajas, Aurora

AU - Massimino, Maura

AU - Reddingius, Roel

AU - Benesch, Martin

AU - Carrie, Christian

AU - Taylor, Roger

AU - Gandola, Lorenza

AU - Björk-Eriksson, Thomas

AU - Giralt, Jordi

AU - Oldenburger, Foppe

AU - Pietsch, Torsten

AU - Figarella-Branger, Dominique

AU - Robson, Keith

AU - Forni, Marco

AU - Clifford, Steven C

AU - Warmuth-Metz, Monica

AU - von Hoff, Katja

AU - Faldum, Andreas

AU - Mosseri, Véronique

AU - Kortmann, Rolf

PY - 2012

Y1 - 2012

N2 - To compare event-free survival (EFS), overall survival (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed by maintenance chemotherapy.

AB - To compare event-free survival (EFS), overall survival (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed by maintenance chemotherapy.

KW - Humans

KW - Male

KW - Female

KW - Adolescent

KW - Child

KW - Survival Rate

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Child, Preschool

KW - Recurrence

KW - Chemotherapy, Adjuvant

KW - Cranial Irradiation

KW - Radiotherapy, Adjuvant

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Cerebellar Neoplasms/radiotherapy

KW - Dose Fractionation

KW - Hearing Loss/etiology

KW - Medulloblastoma/radiotherapy

KW - Humans

KW - Male

KW - Female

KW - Adolescent

KW - Child

KW - Survival Rate

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Child, Preschool

KW - Recurrence

KW - Chemotherapy, Adjuvant

KW - Cranial Irradiation

KW - Radiotherapy, Adjuvant

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Cerebellar Neoplasms/radiotherapy

KW - Dose Fractionation

KW - Hearing Loss/etiology

KW - Medulloblastoma/radiotherapy

M3 - SCORING: Journal article

VL - 30

SP - 3187

EP - 3193

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 26

M1 - 26

ER -